Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GHASSAN E HADI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1558497891
CMS profile
70065
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$24.75

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $24.75 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI-AVENTIS U.S. LLC $24.75 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GHASSAN E HADI

NPI 1558497891 · CMS profile ID 70065

Allopathic & Osteopathic Physicians / Internal Medicine

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558497891?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558497891?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558497891?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
GHASSAN E HADI, NPI 1558497891, CMS profile ID 70065, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1558497891?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $24.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $24.7503/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744138773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $263.01 5
PY2020 $24.75 1
PY2021 $62.66 3
PY2022 $58.25 3
PY2023 $50.93 3
PY2024 $113.96 5
PY2025 $389.94 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,708.88 2
PY2024 Principal investigator $420,960.28 70
PY2023 Principal investigator $204,323.13 66
PY2022 Recipient $16,223.02 2
PY2022 Principal investigator $153,397.33 18
PY2021 Principal investigator $215,215.05 24
PY2020 Principal investigator $212,670.33 84
PY2019 Principal investigator $457,066.36 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

176 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $601.63 12/31/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
OPEN-LABEL EXTENSION STUDY OF RELAMORELIN FOR THE TREATMENT OF DIABETIC GASTROPARESIS DG No dispute reported 06/30/2026 670119620
Principal investigator 1 Allergan Inc. $11,501.43 12/31/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670120495
Principal investigator 1 Allergan Inc. $86,518.40 12/31/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670124119
Principal investigator 1 Allergan Inc. $2,261.26 12/31/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670124693
Principal investigator 1 Allergan Inc. $31,305.35 12/17/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670116559
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 12/16/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189221
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 12/16/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189223
Principal investigator 1 Allergan Inc. $8,635.50 12/16/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670111545
Principal investigator 1 Allergan Inc. $1,140.00 12/16/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670111785
Principal investigator 1 Allergan Inc. $1,187.50 12/11/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670108377
Principal investigator 1 Allergan Inc. $1,634.00 12/11/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670108485
Principal investigator 1 Allergan Inc. $1,140.00 12/11/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670108547
Principal investigator 1 Allergan Inc. $686.00 12/10/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670107265
Principal investigator 1 Allergan Inc. $630.00 12/10/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670107507
Principal investigator 1 AKEBIA THERAPEUTICS INC $970.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189203
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189205
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189207
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189209
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189211
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189213
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189215
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189217
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 12/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189219
Principal investigator 1 AKEBIA THERAPEUTICS INC $7,461.00 12/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189199
Principal investigator 1 AKEBIA THERAPEUTICS INC $39.82 12/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189201
Principal investigator 1 Allergan Inc. $700.00 12/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670105491
Principal investigator 1 Allergan Inc. $200.00 12/03/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670105844
Principal investigator 1 Allergan Inc. $955.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100129
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100161
Principal investigator 1 Allergan Inc. $420.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100275
Principal investigator 1 Allergan Inc. $230.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100333
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100413
Principal investigator 1 Allergan Inc. $115.00 11/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670100593
Principal investigator 1 Allergan Inc. $2,118.50 11/15/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670098721
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189159
Principal investigator 1 AKEBIA THERAPEUTICS INC $998.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189161
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189163
Principal investigator 1 AKEBIA THERAPEUTICS INC $865.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189165
Principal investigator 1 AKEBIA THERAPEUTICS INC $865.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189167
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189169
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189171
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189173
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189175
Principal investigator 1 AKEBIA THERAPEUTICS INC $783.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189177
Principal investigator 1 AKEBIA THERAPEUTICS INC $783.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189179
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189181
Principal investigator 1 AKEBIA THERAPEUTICS INC $998.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189183
Principal investigator 1 AKEBIA THERAPEUTICS INC $984.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189185
Principal investigator 1 AKEBIA THERAPEUTICS INC $984.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189187
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189189
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189191
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189193
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189195
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 11/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189197
Principal investigator 1 Allergan Inc. $1,634.00 10/28/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670091773
Principal investigator 1 Allergan Inc. $3,201.50 10/07/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670082609
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,378.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189095
Principal investigator 1 AKEBIA THERAPEUTICS INC $150.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189097
Principal investigator 1 AKEBIA THERAPEUTICS INC $81.60 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189099
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189101
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,106.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189103
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189105
Principal investigator 1 AKEBIA THERAPEUTICS INC $943.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189107
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189109
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189111
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189113
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189115
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189117
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189119
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189121
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189123
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,106.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189125
Principal investigator 1 AKEBIA THERAPEUTICS INC $865.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189127
Principal investigator 1 AKEBIA THERAPEUTICS INC $865.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189129
Principal investigator 1 AKEBIA THERAPEUTICS INC $865.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189131
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189133
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189135
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189137
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189139
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189141
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,106.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189143
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,096.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189145
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,096.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189147
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,096.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189149
Principal investigator 1 AKEBIA THERAPEUTICS INC $983.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189151
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189153
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189155
Principal investigator 1 AKEBIA THERAPEUTICS INC $81.60 10/01/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189157
Principal investigator 1 Allergan Inc. $8,000.00 09/12/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074829
Principal investigator 1 Allergan Inc. $260.00 09/12/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074847
Principal investigator 1 Allergan Inc. $171.00 09/12/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670074907
Principal investigator 1 AKEBIA THERAPEUTICS INC $943.00 09/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189089
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 09/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189091
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 09/04/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189093
Principal investigator 1 Allergan Inc. $3,591.00 08/30/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670070945
Principal investigator 1 Allergan Inc. $1,007.00 08/30/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670071001
Principal investigator 1 Allergan Inc. $4,000.00 08/29/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670070703
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 08/12/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189083
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 08/12/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189085
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 08/12/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189087
Principal investigator 1 AKEBIA THERAPEUTICS INC $24,477.00 07/24/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189077
Principal investigator 1 AKEBIA THERAPEUTICS INC $825.00 07/24/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189079
Principal investigator 1 AKEBIA THERAPEUTICS INC $66.83 07/24/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189081
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189057
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,106.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189059
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,096.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189061
Principal investigator 1 AKEBIA THERAPEUTICS INC $956.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189063
Principal investigator 1 AKEBIA THERAPEUTICS INC $943.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189065
Principal investigator 1 AKEBIA THERAPEUTICS INC $943.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189067
Principal investigator 1 AKEBIA THERAPEUTICS INC $943.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189069
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189071
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189073
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 07/09/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189075
Principal investigator 1 Allergan Inc. $6,711.75 07/09/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670055365
Principal investigator 1 Allergan Inc. $1,007.00 06/18/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670051957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,878.00 06/17/2019 Non-covered Recipient Entity
Ghassan E Hadi Md
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis No dispute reported 06/30/2026 684981461
Principal investigator 1 Allergan Inc. $1,672.00 05/07/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670043649
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189023
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189025
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189027
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189029
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189031
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189033
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189035
Principal investigator 1 AKEBIA THERAPEUTICS INC $248.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189037
Principal investigator 1 AKEBIA THERAPEUTICS INC $248.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189039
Principal investigator 1 AKEBIA THERAPEUTICS INC $880.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189041
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189043
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189045
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189047
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189049
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189051
Principal investigator 1 AKEBIA THERAPEUTICS INC $805.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189053
Principal investigator 1 AKEBIA THERAPEUTICS INC $674.00 05/03/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189055
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188987
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188989
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188991
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188993
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188995
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188997
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707188999
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189001
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189003
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189005
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189007
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189009
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189011
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189013
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189015
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189017
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189019
Principal investigator 1 AKEBIA THERAPEUTICS INC $63.00 04/23/2019 Non-covered Recipient Entity
GHASSAN HADI MD INC
AKB-6548-CI-0014 No dispute reported 06/30/2026 707189021
Principal investigator 1 Allergan Inc. $10,668.50 04/23/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670039398
Principal investigator 1 Allergan Inc. $3,671.75 04/22/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670039157
Principal investigator 1 Allergan Inc. $1,007.00 04/22/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670039193
Principal investigator 1 Allergan Inc. $1,634.00 04/19/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670038947
Principal investigator 1 Allergan Inc. $1,634.00 04/19/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH GHASSAN HADI MD INC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670039107
Principal investigator 1 Allergan Inc. $140.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034009
Principal investigator 1 Allergan Inc. $725.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034137
Principal investigator 1 Allergan Inc. $140.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034173
Principal investigator 1 Allergan Inc. $300.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034261
Principal investigator 1 Allergan Inc. $171.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034269
Principal investigator 1 Allergan Inc. $600.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034367
Principal investigator 1 Allergan Inc. $12,000.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034467
Principal investigator 1 Allergan Inc. $20,000.00 03/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670034795
Principal investigator 1 SANOFI PASTEUR INC. $34,760.50 02/28/2019 Non-covered Recipient Entity
Ghassan Hadi MD DBA Upland Clinical Research
H 030 014 Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection No dispute reported 06/30/2026 691620879
Principal investigator 1 Allergan Inc. $2,688.50 02/26/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670026917
Principal investigator 1 Allergan Inc. $7,676.00 01/29/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670019803
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,051.40 01/28/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
AKB-6548-CI-0015 No dispute reported 06/30/2026 707188981
Principal investigator 1 AKEBIA THERAPEUTICS INC $972.42 01/28/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
AKB-6548-CI-0015 No dispute reported 06/30/2026 707188983
Principal investigator 1 AKEBIA THERAPEUTICS INC $973.62 01/28/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
AKB-6548-CI-0015 No dispute reported 06/30/2026 707188985
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,188.00 01/24/2019 Non-covered Recipient Entity
Ghassan E Hadi Md
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) No dispute reported 06/30/2026 684981467
Principal investigator 1 Allergan Inc. $1,738.50 01/22/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670018449
Principal investigator 1 Allergan Inc. $950.00 01/15/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A 46-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 LONGTERM STUDY WITH A 6-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE SAFETY AND No dispute reported 06/30/2026 670016429
Principal investigator 1 Allergan Inc. $4,000.00 01/10/2019 Non-covered Recipient Entity
UPLAND CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670016169
Principal investigator 1 SANOFI PASTEUR INC. $9,621.50 01/10/2019 Non-covered Recipient Entity
Ghassan Hadi MD DBA Upland Clinical Research
H 030 014 Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection No dispute reported 06/30/2026 691615627